Parkinson’s disease with mild cognitive impairment may have a lower risk of cognitive decline after subthalamic nucleus deep brain stimulation: A retrospective cohort study

Hutao Xie¹, Quan Zhang¹, Yin Jiang²,³*, Yutong Bai¹* and Jianguo Zhang¹,²,³*

¹Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China, ²Beijing Key Laboratory of Neurostimulation, Beijing, China, ³Department of Functional Neurosurgery, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China

Background: The cognitive outcomes induced by subthalamic nucleus deep brain stimulation (STN-DBS) remain unclear, especially in PD patients with mild cognitive impairment (MCI). This study explored the cognitive effects of STN-DBS in PD patients with MCI.

Methods: This was a retrospective cohort study that included 126 PD patients who underwent STN-DBS; all patients completed cognitive and motor assessments before and at least 6 months after surgery. Cognitive changes were mainly evaluated by the Montreal cognitive assessment (MoCA) scale and the seven specific MoCA domains, including visuospatial/executive function, naming, attention, language, abstract, delayed recall, and orientation. Motor improvement was evaluated by the UPDRS-III. Cognitive changes and motor improvements were compared between PD-MCI and normal cognitive (NC) patients. Logistic regression analyses were performed to explore predictors of post-operative cognitive change.

Results: At the time of surgery, 61.90% of the included PD patients had MCI. Compared with the PD-MCI group, the PD-NC group had a significantly higher proportion of cases with post-operative cognitive decline during follow-up of up to 36 months (mean 17.34 ± 10.61 months), mainly including in global cognitive function, visuospatial/executive function and attention. Covariate-adjusted binary logistic regression analyses showed that pre-operative global cognitive status was an independent variable for post-operative cognitive decline. We also found that pre-operative cognitive
Introduction

Subthalamic nucleus (STN) deep brain stimulation (DBS) has become a well-established treatment for alleviating motor symptoms and reducing the dose of dopaminergic medicine in patients with advanced Parkinson’s disease (PD) (Bronstein et al., 2011; Rughani et al., 2018). But accumulated evidence has shown that subthalamic nucleus deep brain stimulation (STN-DBS) has negative effects on cognitive function in patients with both normal cognitive (NC) and mild cognitive impairment (MCI) (Parsons et al., 2006; Smeding et al., 2011; Kim et al., 2014; Merola et al., 2014; Combs et al., 2015; Odkerken et al., 2015; Cernera et al., 2019; Gruber et al., 2019). MCI represents a transitional cognitive status from normal cognition (NC) to dementia (PDD), and it is common in PD patients, with a prevalence as high as 40% (Hoogland et al., 2017; Gruber et al., 2019; Baiano et al., 2020).

There are relatively few studies on the cognitive outcomes of STN-DBS in PD-MCI patients, and the existing studies have primarily focused on the rate or risk of progression to PDD. These studies have generally shown that PD-MCI patients are at greater risk of developing PDD compared with PD-NC patients (Kim et al., 2014; Merola et al., 2014; Gruber et al., 2019; Park et al., 2020). However, post-operative cognitive decline that does not reach sufficient severity for PDD diagnosis, although does diminish patients’ quality of life, has largely been ignored.

The aim of this retrospective cohort study was to investigate whether the rate of post-operative cognitive decline (not only PDD) was higher in PD-MCI patients compared with PD-NC patients after STN-DBS. We also explored potential baseline parameters that could predict post-operative cognitive decline after STN-DBS.

Materials and methods

Patient selection

This was a single center retrospective cohort study. PD patients who underwent STN-DBS between January 2016 and June 2020 were consecutively collected from the database of Beijing Tiantan Hospital (Beijing, China). The inclusion criteria included: (1) idiopathic PD diagnosed according to the UK brain bank criteria; (2) no dementia based on the Mini-Mental State Exam (MMSE) norm for elderly Chinese citizens (MMSE > 20 for individuals with 1–6 years of education and MMSE > 24 for individuals with 7 or more years of education) (Li et al., 2016); (3) bilateral synchronous STN-DBS treatment was performed at Beijing Tiantan Hospital; and (4) complete clinical assessment and follow-up for at least 6 months after STN-DBS. The exclusion criteria included: (1) illiteracy; (2) previous relevant medical history affecting cognitive function (e.g., stroke, brain tumor, hydrocephalus, and brain trauma); (3) serious surgical related complications (e.g., intracerebral hemorrhage); (4) the DBS lead had been revised or replaced; or (5) only online follow-up. This study was approved by the local Institutional Review Board (IRB) (IRB number: KY2020-139-01), all patients provided signed written informed consent.

Surgical procedures

All operations were performed by the same surgical team, and the surgical process was as described in previous studies in detail (Fan et al., 2020; Yin et al., 2021). Briefly, under local anesthesia, DBS electrodes (model 3,389, Medtronic, Dublin, Ireland, or model L301, Pins Medical, Beijing, China) were implanted with the Leksell micro stereotactic system (Elekta Instrument AB, Stockholm, Sweden). Microelectrode recording and macro stimulation tests were performed for trajectory selection. Then, an implantable pulse generator was implanted into the subclavian region under general anesthesia. Computed tomography scans were performed 1 day after surgery to eliminate complications such as intracranial hemorrhage. The implantable pulse generator was turned on 1 month after the operation. Since then, each patient underwent a regular adjustment of stimulation parameter settings and medication until symptoms were optimally controlled, usually at 6 months after surgery.
Cognitive and clinical assessment

Cognitive and clinical assessments primarily included cognitive function assessment [i.e., MMSE (Chinese version) and Montreal cognitive assessment (MoCA; Beijing version)], motor function assessment [i.e., Unified Parkinson’s Disease Rating Scale (UPDRS) or Movement Disorder Society (MDS)-UPDRS], and global cognitive status (PD-NC and PD-MCI, defined by pre-operative overall MoCA score). This study used 50-years-old as the cut-off value for age of onset, and PD patients were divided into early-onset PD (<50) and late-onset PD (≥50) (Schrag and Schott, 2006). Hoehn–Yahr stage was only collected in the med-off state. Levodopa responsiveness was calculated as (UPDRS-III [med-off]–UPDRS-III [med-on])/UPDRS-III [med-off] × 100%. It should be noted that because some patients were assessed with UPDRS and others with MDS-UPDRS (the scale used for each patient was consistent during follow-up), UPDRS-III scores were uniformly converted to MDS-UPDRS-III using the previously reported method (Goetz et al., 2012).

Dichotomy of post-operative cognitive decline in individual patients and incidence of post-operative Parkinson’s disease dementia

Pre-operative cognitive status was assessed using the overall MoCA scores. PD-MCI was defined by MoCA scores of ≤19 for individuals with 1–6 years of education and 24 for individuals with 7 or more years of education based on the norms for elderly Chinese citizens (Lu et al., 2011)] following MDS diagnostic criteria level I (Litvan et al., 2012). PDD was clinically defined according to MDS diagnostic criteria level I (Dubois et al., 2007). Briefly, MMSE score < 20 for individuals with 1–6 years of education and MMSE < 24 for individuals with 7 or more years of education based on the MMSE norm for elderly Chinese citizens. Based on the changes in MoCA score after STN-DBS, patients were divided into the cognitive-decline and non-cognitive-decline groups. A decrease in MoCA score of ≥1.5 standard deviations (SDs) from baseline was defined as individual cognitive decline. Considering that MoCA scores are integers, we rounded 2 points as the cut-off (Lu et al., 2011). And we subtracted 1 point as the cut-off for each specific domain, such as in visuospatial/executive function, naming, attention, language, abstract, delayed recall, and orientation. In addition, the incidence of decline in the MMSE score (2 points as the cut-off) during the follow-up was also calculated (Stein et al., 2012).

In addition, the percentage of decline in the MMSE score (2 points as the cut off) during the follow-up was also calculated (Stein et al., 2012).

Potential predictors of post-operative cognitive decline

We collected baseline information from PD patients as potential predictors of cognitive decline, including gender, age at surgery, age of onset, disease duration, education, Hoehn–Yahr stage (med-off), MDS-UPDRS-III (med-off), levodopa responsiveness, symptom onset side, LEDD and pre-operative global cognitive status (PD-NC and PD-MCI, defined by pre-operative overall MoCA score). This study used 50-years-old as the cut-off value for age of onset, and PD patients were divided into early-onset PD (<50) and late-onset PD (≥50) (Schrag and Schott, 2006). Hoehn–Yahr stage was only collected in the med-off state. Levodopa responsiveness was calculated as (UPDRS-III [med-off]–UPDRS-III [med-on])/UPDRS-III [med-off] × 100%. It should be noted that because some patients were assessed with UPDRS and others with MDS-UPDRS (the scale used for each patient was consistent during follow-up), UPDRS-III scores were uniformly converted to MDS-UPDRS-III using the previously reported method (Goetz et al., 2012).

Statistical analysis

Descriptive statistics were used to describe baseline and follow-up demographic data. Continuous variables are described as mean (±SD), while categorical variables are expressed as percentages. Intergroup comparisons of demographic data between patients were performed by applying either the independent t-test for continuous variables or the chi-square test for binary variables.

First, in order to investigated whether there were differences in cognitive decline after STN-DBS between the two groups, the two-way repeated-measures ANOVA were performed, with group (PD-MCI and PD-NC) as the between-group factor and time (before and after DBS) as the within-group factor, followed by Bonferroni’s post-hoc tests. Proportions of post-operative cognitive decline at last follow-up as well as the rate of cognitive decline at each follow-up time point were compared between groups using the Chi-square or Fisher’s exact test. In addition, incidence of post-operative PDD were also compared between groups using the Chi-square test. Second, we evaluated baseline variables that could predict cognitive decline using univariate logistic regression models. Because no consistent predictors have been identified in previous studies, we included all available parameters as an exploratory analysis, the stepwise forward approach was used to input these measurements as independent variables into the multivariable logistic regression.
model. Then, we also used the logistic regression model to explore possible baseline cognitive variables that could predict decline in cognitive specific domains following STN-DBS. Two tailed p-values < 0.05 were considered significant. Reported p-values were corrected for multiple comparisons in the domain analysis using the Bonferroni test (initial α = 0.05). All statistical analyses were performed using The R Project for Statistical Computing (version 3.6.1).\(^1\)

**Results**

**Baseline characteristics of the Parkinson’s disease-mild cognitive impairment and Parkinson’s disease-normal cognition groups**

The detailed workflow is shown in Figure 1. A total of 126 PD patients were ultimately included in this study. Among the included patients, 61.90% had MCI status at the time of surgery. As shown in Table 1, the PD-MCI group had lower MMSE (PD-MCI: 26.73 ± 2.12; PD-NC: 28.15 ± 1.90) and MoCA (PD-MCI: 19.33 ± 3.39; PD-NC: 25.19 ± 1.79) scores, decreased scores in all the specific cognitive domain of MoCA, and fewer years of education. The two groups did not differ significantly in any other baseline characteristics.

**Post-operative decline in cognitive test scores between groups**

We have presented the results of two-way repeated-measures ANOVA in Figure 2 and Supplementary Table 1. Mean cognitive test scores significantly decreased following STN-DBS on indices of MMSE ($F=20.35$, $p<0.001$) and MoCA ($F=36.12$, $p<0.001$), as well as MoCA specific domains, including visuospatial/executive function ($F=12.72$, $p<0.001$), attention ($F=26.25$, $p<0.001$) and language ($F=29.77$, $p<0.001$). Post hoc analyses revealed that, for MMSE (Figure 2A; PD-MCI: $t=3.45$, $p=0.002$; PD-NC: $t=3.03$, $p=0.006$) and language (Figure 2F; PD-MCI: $t=3.51$, $p=0.001$; PD-NC: $t=4.18$, $p<0.001$), both groups demonstrated significant post-operative decline. While

| Variables | PD-MCI ($n=78$) | PD-NC ($n=48$) | P-value |
|-----------|----------------|----------------|---------|
| Gender/female (%)\(^a\) | 37 (47.44%) | 17 (35.42%) | 0.186 |
| Age of surgery (years) | 62.88 ± 8.45 | 61.69 ± 8.58 | 0.444 |
| Age of onset/late onset (%)\(^a\) | 52 (66.67%) | 33 (68.73%) | 0.808 |
| Duration of disease (years) | 9.72 ± 4.28 | 8.92 ± 3.49 | 0.277 |
| Education (years) | 9.96 ± 2.96 | 11.92 ± 3.00 | <0.001\(^*\) |
| Hoehn Yahr stage (med off) | 2.96 ± 0.57 | 3.01 ± 0.63 | 0.650 |
| LEDD (mg) | 711.82 ± 368.24 | 749.14 ± 499.51 | 0.598 |
| MDS-UPDRS-III (med off) | 55.11 ± 19.06 | 58.03 ± 21.52 | 0.428 |
| Levodopa responsiveness (%) | 50.35 ± 19.26 | 52.16 ± 17.12 | 0.652 |
| Symptom onset side (left/right/bilateral)\(^a\) | 32/39/2 | 19/21/5 | 0.169 |
| MMSE score | 26.73 ± 2.12 | 28.15 ± 1.90 | <0.001\(^*\) |
| MoCA score | 19.21 ± 3.81 | 25.19 ± 1.79 | <0.001\(^*\) |
| MoCA specific domains score | 2.37 ± 1.43 | 3.96 ± 1.01 | <0.001\(^*\) |
| Visuospatial/executive function score | 2.53 ± 0.83 | 2.90 ± 0.31 | 0.004\(^*\) |
| Naming score | 4.94 ± 1.30 | 5.65 ± 0.56 | <0.001\(^*\) |
| Attention score | 1.90 ± 0.85 | 2.58 ± 0.61 | <0.001\(^*\) |
| Language score | 0.87 ± 0.84 | 1.56 ± 0.54 | <0.001\(^*\) |
| Abstract score | 1.08 ± 1.09 | 2.71 ± 1.32 | 0.025\(^*\) |
| Delayed recall score | 5.42 ± 1.19 | 5.83 ± 0.48 | <0.001\(^*\) |

\(^a\)Chi-square test; unindicated comparisons were conducted using the independent t-test; Significant results are marked with\(^*\).

PD-MCI, Parkinson’s disease with mild cognitive impairment; PD-NC, Parkinson’s disease with normal cognition; LEDD, Levodopa equivalent dose; MDS-UPDRS-III (med-off), Movement Disorder Society-Unified Parkinson’s Disease Rating Scale, Part III (med-off), MoCA, Montreal Cognitive Assessment, MMSE, Mini-Mental State Examination (off medication).

---

\(^1\)https://www.rstudio.com/
Comparison of pre- and post-operative cognitive scores between groups. Compare to pre-operative, (A) overall MMSE scores (PD-MCI: \( \ast \ast p = 0.002 \); PD-NC: \( \ast \ast p = 0.006 \)) and language scores (PD-MCI: \( \ast \ast \ast p = 0.001 \); PD-NC: \( \ast \ast \ast p < 0.001 \)) showed decline in PD-MCI and PD-NC groups. (B) Overall MoCA scores (\( \ast \ast \ast p < 0.001 \)), (C) visuospatial/executive function (\( \ast \ast \ast p < 0.001 \)) and (E) attention (\( \ast \ast \ast p < 0.001 \)) showed significant post-operative decline in PD-NC group. Compare to PD-NC group, PD-MCI group showed lower score in (A) overall MMSE (pre-operative: \( \ast \ast p = 0.009 \); post-operative: \( \ast p = 0.02 \)), (B) overall MoCA (pre-operative: \( \ast \ast \ast p < 0.001 \); post-operative: \( \ast \ast \ast p < 0.001 \)), (C) visuospatial/executive function (pre-operative: \( \ast \ast \ast p < 0.001 \); post-operative: \( \ast \ast \ast p < 0.001 \)), (D) naming (pre-operative: \( \ast \ast \ast p = 0.007 \); post-operative: \( \ast \ast \ast p = 0.003 \)), (F) language (pre-operative: \( \ast \ast \ast p < 0.001 \); post-operative: \( \ast \ast \ast p = 0.004 \)), (G) abstract (pre-operative: \( \ast \ast \ast p < 0.001 \); post-operative: \( \ast p = 0.013 \)), and (H) delayed recall (pre-operative: \( \ast \ast \ast p < 0.001 \); post-operative: \( \ast \ast \ast p < 0.001 \)) in both pre- and post-operative, and (E) attention (\( \ast \ast \ast p < 0.001 \)) in pre-operative. No significant difference was found in orientation (between pre- and postoperative within-group, or between-groups) (I). The data were analyzed by two-way repeated-measures ANOVA with group (PD-MCI and PD-NC) as the between group factor and time (before and after DBS) as the within group factor, followed by Bonferroni’s post-hoc tests. All graphs are depicted with bars for standard errors of the mean (SEM) and \( p \)-values (two-tailed) with the following significance level: \( \ast \ast p < 0.01 \); \( \ast \ast \ast p < 0.001 \) (within-group comparison); \( \ast p < 0.05 \); \( \ast \ast p < 0.01 \); \( \ast \ast \ast p < 0.001 \) (between-group comparison). PD-MCI, Parkinson’s disease with mild cognitive impairment; PD-NC, Parkinson’s disease with normal cognition; MoCA, Montreal Cognitive Assessment; MMSE, Mini-Mental State Examination.
rates of post-operative cognitive decline between groups.

The comparison of post-operative cognitive decline rates at last follow-up between PD-MCI and PD-NC groups are displayed in Table 2. Mean duration of follow-up seemed to be longer in the PD-NC group than in the PD-MCI group, but group differences were not statistically significant (p = 0.324). At last follow-up, significant decline rate of MMSE (PD-MCI: 29.49%; PD-NC: 22.92%), MoCA (PD-MCI: 30.77%; PD-NC: 56.25%), and MoCA specific domains, including visuospatial/executive function (PD-MCI: 33.33%; PD-NC: 56.25%), attention (PD-MCI: 43.59%; PD-NC: 62.50%) and language (PD-MCI: 42.31%; PD-NC: 47.92%) were observed in both groups after STN-DBS. And a higher proportion of post-operative PDD cases were also found in the PD-MCI group compared with PD-NC group (19.20% vs. 6.25%, p = 0.043) (Table 2). There was a higher percentage of patients with decreased MoCA scores in the PD-NC group than in the PD-MCI group (p = 0.005). Furthermore, the PD-NC group showed a higher proportion of declines in specific MoCA domains including visuospatial/executive function, attention and delayed recall. Both groups had an excellent rate of improvement in MDS-UPDRS-III after surgery, with no significant difference found between the two groups (p = 0.081).

To eliminate the influence of follow-up duration, we further stratified results by follow-up time (6, 12, 24, and 36 months). The results are displayed in Table 3. At 24 and 36 months following STN-DBS, the decline rates of MoCA (24 months, PD-MCI: 31.25%, PD-NC: 77.78%, p = 0.041; 36 months, PD-MCI: 25.00%, PD-NC: 75.00%, p = 0.039) and visuospatial/executive function (24 months, PD-MCI: 25.00%, PD-NC: 77.78%, p = 0.017; 36 months, PD-MCI: 25.00%, PD-NC: 75.00%, p = 0.039) were significantly higher in the PD-NC group compared to that in the PD-MCI group. We also found attention remained significantly higher in the PD-NC (56.25%) compared to PD-MCI group (22.58%) at 12 months after surgery (p = 0.021). Although the decline rates of delayed recall (memory) in the PD-NC group were higher than those in the PD-MCI group at each follow-up timepoint, there were no significant differences between the two groups (Table 3).

Pre-operative predictors of post-operative cognitive decline

Two potential baseline predictors of cognitive decline were entered into multivariate logistic regression models: pre-operative global cognitive status (PD-NC and PD-MCI, defined by pre-operative MoCA score) [odds ratio (OR): 2.89, 95% confidence interval (CI): 1.37–6.10, p = 0.005] and UPDRS-III (med-off) [OR: 0.98, 95%CI: 0.97–1.00, p = 0.084; Table 4]. The multivariate logistic regression model was adjusted twice.

### Table 2 Percentages of cognitive decline and rates of improved MDS-UPDRS-III outcomes at the last follow-up between the PD-MCI and PD-NC groups.

| Variables                  | PD-MCI (n = 78) | PD-NC (n = 48) | P-value |
|----------------------------|----------------|----------------|---------|
| Follow-up (months)*        | 16.08 ± 10.48  | 18.78 ± 11.43  | 0.324   |
| Decline of MMSE            | 23 (29.49%)    | 11 (22.92%)    | 0.420   |
| Decline of MoCA            | 24 (30.77%)    | 27 (36.25%)    | 0.005*  |
| Decline of MoCA specific domains | 26 (33.33%) | 27 (36.25%) | 0.011* |
| Visuospatial/Executive function | 9 (11.54%) | 3 (6.25%) | 0.326 *
| Attention                  | 34 (43.59%)    | 30 (62.50%)    | 0.039*  |
| Language                   | 33 (42.31%)    | 23 (47.92%)    | 0.538   |
| Abstract                   | 19 (24.36%)    | 10 (20.83%)    | 0.648   |
| Delayed recall             | 12 (15.38%)    | 20 (41.67%)    | <0.001* |
| Orientation                | 21 (26.92%)    | 8 (16.67%)     | 0.184   |
| PDD                        | 15 (19.20%)    | 3 (6.25%)      | 0.043*  |
| Improvement rate of MDS-UPDRS-III (%) | 45.37 ± 24.16 | 54.24 ± 30.36 | 0.081 *

*Independent t-test; undichotomized comparisons were conducted using Chi-square tests or Fisher’s exact test. Significant results are marked with *. PD-MCI: Parkinson’s disease with mild cognitive impairment; PD-NC: Parkinson’s disease with normal cognition; MoCA: Montreal Cognitive Assessment, MMSE, Mini-Mental State Examination; MDS-UPDRS-III: Movement Disorder Society-Unified Parkinson’s Disease Rating Scale, Part III, PDD: Parkinson’s disease dementia.
TABLE 3 Percentages of cognitive decline at each follow-up timepoint between the PD-MCI and PD-NC groups.

| Decline rates | 6 months | 12 months | 24 months | 36 months |
|---------------|----------|-----------|-----------|-----------|
| PD-MCI (n=19) | MMSE     | 6 (31.58%)| 1 (9.10%) | <0.001    |
|               | PD-NC (n=11)| 6 (54.55%)| 4 (36.36%)| <0.001    |
|               | MoCA     | 8 (42.11%)| 5 (45.45%)| <0.001    |
|               | PD-NC (n=11)| 8 (72.73%)| 6 (54.55%)| <0.001    |
|               | Visuospatial/executive | 7 (36.84%)| 4 (36.36%)| <0.001    |
|               | PD-NC (n=11)| 12 (109.09%)| 6 (54.55%)| <0.001    |
|               | Naming   | 2 (10.53%)| 0 (0.00)  | <0.001    |
|               | PD-NC (n=11)| 4 (36.36%)| 2 (18.18%)| <0.001    |
|               | Attention| 5 (26.32%)| 5 (45.45%)| <0.001    |
|               | PD-NC (n=11)| 5 (45.45%)| 5 (45.45%)| <0.001    |
|               | Language | 4 (21.05%)| 5 (45.45%)| <0.001    |
|               | PD-NC (n=11)| 4 (36.36%)| 4 (36.36%)| <0.001    |
|               | Delayed recall | 4 (21.05%)| 5 (45.45%)| <0.001    |
|               | PD-NC (n=11)| 4 (36.36%)| 4 (36.36%)| <0.001    |
|               | Operation | 5 (26.32%)| 5 (45.45%)| <0.001    |

Comparisons were conducted using Chi-square tests or Fisher's exact test; Significant comparisons are marked with *.

PD-MCI, Parkinson's disease with mild cognitive impairment; PD-NC, Parkinson's disease with normal cognition; MoCA, Montreal Cognitive Assessment; MMSE, Mini-Mental State Examination.

TABLE 4 Impact of pre-operative cognitive status, clinical and demographic data on post-operative cognitive decline (univariate logistic regression models).

| Variables                      | OR   | 95% CI       | P-value |
|--------------------------------|------|--------------|---------|
| Gender/female (%)              | 0.89 | (0.43, 1.83) | 0.753   |
| Age of surgery (years)         | 1.00 | (0.96, 1.04) | 0.895   |
| Age of onset/late onset         | 0.94 | (0.44, 2.01) | 0.875   |
| Duration of disease (years)     | 1.02 | (0.93, 1.11) | 0.715   |
| Education (years)               | 1.00 | (0.89, 1.13) | 0.952   |
| Hoehn Yahr stage (med off)      | 0.78 | (0.42, 1.45) | 0.436   |
| LEDD (mg)                      | 1.00 | (1.00, 1.00) | 0.112   |
| MDS-UPDRS-III (med off)        | 0.98 | (0.97, 1.00) | 0.848   |
| Levodopa responsiveness (%)    | 1.18 | (0.17, 8.27) | 0.870   |
| Symptom onset side/ right       | 0.95 | (0.45, 2.04) | 0.900   |
| Symptom onset side/bilateral    | 1.90 | (0.39, 9.41) | 0.430   |
| Pre-operative cognitive status/PD-NC | 2.89 | (1.37, 6.10) | 0.005   |

Significant comparisons are marked with *.

PD-NC, Parkinson’s disease with normal cognition; LEDD, Levodopa equivalent dose; MDS-UPDRS-III (med-off), Movement Disorder Society-Unified Parkinson’s Disease Rating Scale, Part ty(med-off); MoCA, Montreal Cognitive Assessment; MMSE, Mini-Mental State Examination (off medication). OR, odds ratio; CI, confidence interval.

Discussion

In this study, first, we compared the pre- and post-operative cognitive scores as well as proportions of post-operative cognitive decline of PD patients with different pre-operative cognitive status (including PD-NC and PD-MCI, defined by pre-operative overall MoCA score). Results of cognitive scores showed that global cognition (MoCA and MMSE), visuospatial/executive function, attention, and language scores significantly decreased in both groups following STN-DBS, and
TABLE 5  Impact of pre-operative cognitive status (PD-NC) and MDS-UPDRS-III (med-off) on post-operative cognitive decline (multivariate logistic regression models).

| Variables                  | Non-adjusted |          |          |          | Adjust -I |          |          |          | Adjust -II |          |          |
|----------------------------|--------------|----------|----------|----------|-----------|----------|----------|----------|-----------|----------|----------|
|                            | OR 95% CI    | P-value  | OR 95% CI | P-value  | OR 95% CI | P-value  | OR 95% CI | P-value  |
| Pre-operative cognitive status/PD-NC | 2.832 (1.332, 6.020) | 0.007*   | 2.968 (1.357, 6.492) | 0.006*   | 2.961 (1.191, 7.357) | 0.020*   |
| MDS-UPDRS-III (med off)    | 1.015 (0.996, 1.035) | 0.113    | 1.019 (0.999, 1.040) | 0.060    | 1.019 (0.994, 1.045) | 0.136    |

Significant comparisons are marked with *; non-adjusted model adjusted for: none; adjusted model I adjusted for: age and gender; adjusted model II adjusted for: age, gender, age of onset, education, Hoehn–Yahr stage (med-off), and symptom onset side.

PD-NC, Parkinson’s disease with normal cognition; LEDD, Levodopa equivalent dose; MDS-UPDRS-III (med-off), Movement Disorder Society-Unified Parkinson’s Disease Rating Scale, Part III (off medication); OR: odds ratio; CI, confidence interval.

greater post-operative cognitive decline in patients with PD-NC compared to PD-MCI on MoCA, visuospatial/executive function and attention scores. The percentage of patients with post-operative cognitive decline at last follow-up was higher in the PD-NC group compared with the PD-MCI group, including overall MoCA, visuospatial/executive function, attention, and delayed recall (memory). However, when stratifying by duration of follow-up, results showed that decline rates of overall MoCA (at 24 and 36 months after surgery) and visuospatial/executive function (at 24 and 36 months after surgery), as well as attention (at 12 months after surgery) remained significantly higher in the PD-NC group compared to that in the PD-MCI group. Then,
potential predictors of post-operative cognitive decline were also explored, which revealed that patients with pre-operative NC status had a significantly higher probability of cognitive decline after STN-DBS than patients with MCI status.

Our data showed that with an average disease duration of 9.41 years, the prevalence of MCI was 61.90% at the time of surgery, which was consistent with previous studies. It was reported that prevalence of MCI was 63.1% among 103 non-demented PD patients with a disease duration of 10.6 years (Kim et al., 2014), similarly, another study reported a 69.08% rate of MCI among 304 PD patients with an average disease duration of 13 years (Park et al., 2020). Notably, the prevalence of MCI was high in our cohort compared with a meta-analysis of 7,053 non-surgery PD patients that had a pooled prevalence of PD-MCI of 40% (Baiano et al., 2020). The differences between their results and those presented herein may be attributable to differences in the patient cohort. In our study, patients mostly had advanced PD, longer disease duration, increased disease severity, and needed surgery. Overall, MCI is highly common among PD patients undergoing DBS surgery, so more attention should be paid to this patient population.

The percentage of patients with post-operative global cognitive (MoCA) decline among all PD patients at the last follow-up (mean 17.52 months) was 40.48%, which was very close to the rate reported by prior work (39.3%), where patients were not classified as PD-NC or PD-MCI at baseline and cognitive decline after 12 months was defined as a significant deterioration of three or more cognitive tests according to the reliable change index (Odekerken et al., 2015). Our findings are also similar with another study, which showed that at the individual level, compared with the control group, 36% of patients in the STN-DBS group showed cognitive decline at 12-month follow-up (Smeding et al., 2011).

In line with prior studies (York et al., 2008; Zangaglia et al., 2009; Kim et al., 2014; Park et al., 2020), this study showed that post-operative MMSE scores of the two groups were significantly lower than pre-operative scores, and significant post-operative decline rate of MMSE scores was also found in both groups, but no statistically significant differences were noticed between groups. In addition, we found that patients with PD-MCI (19.20%) progressed to PDD in higher proportions than patients with PD-NC (6.25%) at the last follow-up, which has been demonstrated by previous studies (Merola et al., 2014; Gruber et al., 2019). It was reported that patients with MCI (46.4%) had a markedly higher prevalence of developing PDD following STN-DBS compared with NC patients (22.2%) after 6.3 years follow-up (Gruber et al., 2019). The post-operative median time for PD-MCI patients to develop PDD was 6.03 years compared with 11.08 years for those with PD-NC (Merola et al., 2014). There have also been several predictive studies that have reported an increased risk of PDD for MCI subjects compared with NC individuals following STN-DBS (Kim et al., 2014; Park et al., 2020).

However, our study showed that the proportion of patients with global cognitive (MoCA) decline in the PD-NC group (56.25%) was higher than in the PD-MCI group (30.77%). Meanwhile, multivariate logistic regression results also confirmed that the risk of cognitive decline after STN-DBS in the PD-NC group was increased compared with the PD-MCI group. The difference between our data and previous studies may be due to the following reasons: (1) we primarily focused on post-operative cognitive decline, not only cases that progressed to PDD; and (2) we used the MoCA scale for cognitive assessment, while other studies have used the MDRS (Gruber et al., 2019), MMSE (Kim et al., 2014; Park et al., 2020), and other comprehensive scales (Merola et al., 2014).

For the decline of specific domains in MoCA, the findings were generally consistent across both methodologies (comparison of change in cognitive scores and analysis the of cognitive decline rate). First, our results demonstrate that both groups showed a significant post-operative decline in terms of visuospatial/executive function, attention and language, which is consistent with these previous studies (York et al., 2008; Okun et al., 2009; Fasano et al., 2010; Merola et al., 2011; Smeding et al., 2011; Georgiev et al., 2021). Second, patients with PD-NC show more declines on visuospatial/executive function and attention, also memory. Of these, visuospatial/executive function and attention remained significantly after considering the influence duration of follow-up.

The findings above can be explained as follows. The STN can be subdivided into three functional zones, including the dorsolateral region connects with motor pathways, the central region connects with associative pathways, and the ventromedial region connects with limbic pathways. Notably, the associative pathway receives mainly inputs from the frontal cortex, and plays an essential role in regulating cognitive function (Karachi et al., 2005; Temel et al., 2005). And substantial overlap between its functional zones as its compact structure (Balaz et al., 2011; Alkermes and Forstmann, 2014). Language, especially verbal fluency relies more on prefrontal and anterior cingulate, premotor cortex and ventral part of the caudate (Cilia et al., 2007; Mikos et al., 2011). In addition to the associative pathway, evidence indicates that there is also a hyper-direct pathway between the STN and frontal cortex through low-frequency interactions that support executive function (Zavala et al., 2014; Kelley et al., 2018). Attention and executive function are inextricably linked. Some even suggested that attention is part of an executive function (Kehagia et al., 2010). Attention is associated with the frontal and parietal cortex (called frontal-parietal network) (Buschman and Miller, 2007). Consequently, cognitive function including executive function, language and attention will likely be influenced by the STN-DBS, as the disruption of frontal-striatal connectivity,
even though clinical DBS was performed on motor sites in the dorsolateral STN. As PD-NC show more declines in visuospatial/executive and attention, it is likely that PD-MCI patients had impairments in these cognitive domains at baseline (Aarsland et al., 2010; Kalbe et al., 2016; Nie et al., 2019), and their post-operative deterioration was not as apparent as in the PD-NC group.

This study also found that the pre-operative status of specific MoCA domains, except for the naming domain, could predict their own decline after STN-DBS. Our findings are generally consistent with prior studies (Odekerken et al., 2015; Hogue et al., 2018). This finding might be explained by the low rate of patients with a post-operative decrease in naming (PD-MCI: 11.54%, PD-NC: 6.25%, total: 9.52%).

There were a few limitations to this study. First, this was a single center retrospective study with its inherent defects, including being subject to bias, even though patients were enrolled consecutively. Our findings need to be confirmed by further prospective longitudinal studies. Second, the present study used only MoCA to determine cognitive status. Nevertheless, comprehensive neuropsychological assessments are not always available or feasible in clinical practice. Despite the limitation, our findings can be considered to provide a reference for clinicians, which reminds us that clinicians need to focus not only on the patients with pre-operative impaired cognitive function but also on the patients with normal cognitive status in future clinical trials, a comprehensive neuropsychological battery test should be employed to assess the cognitive function of PD patients. Actually, a subsequent ongoing study with a larger patient cohort and a more detailed comprehensive neuropsychological battery according to MDS diagnostic criteria level II (Dubois et al., 2007; Litvan et al., 2012) is under way at our center, which will allow for more detailed and accurate analyses of cognitive function. Third, we did not set up a control group of medically treated patients, making it difficult to rule out the impact of disease progression on cognitive decline following STN-DBS.

Conclusion

In conclusion, our data indicated that compared with PD-NC, PD-MCI patients had lower risk of cognitive decline after STN-DBS, and their rate of motor improvement was similar, although PD-MCI patients progressed to PDD in higher proportions than PD-NC individuals.

Data availability statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

Ethics statement

The studies involving human participants were reviewed and approved by the Local Institutional Review Board (IRB) (IRB number: KY2020-139-01). The patients/participants provided their written informed consent to participate in this study.

Author contributions

HX, YB, QZ, YJ, and JZ: conceptualization and resources. HX, YB, and QZ: data curation and investigation. HX and YB: formal analysis, validation, and writing—original draft. JZ: funding acquisition and project administration. HX, YB, YJ, and JZ: methodology. YB, YJ, and JZ: writing—review, editing, and supervision. All authors contributed to the article and approved the submitted version.

Funding

This work was funded by the National Natural Science Foundation of China (81830033 and 61761166004).

Acknowledgments

We thank all the subjects who participated in this study.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fnhum.2022.943472/full#supplementary-material
functions of the subthalamic nucleus in primates. Mov. Disord. 20, 172–180. doi: 10.1002/mds.20302

Kehagia, A. A., Barker, R. A., and Robbins, T. W. (2010). Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson’s disease. Lancet Neurol. 9, 1208–1213. doi: 10.1016/S1474-4422(10)70212-X

Kelley, R., Flouty, O., Emmons, E. B., Kim, Y., Kingston, J., Wessel, J. R., et al. (2018). A human prefrontal-subthalamic circuit for cognitive control. Brain 141, 205–216. doi: 10.1093/brain/awx300

Kim, H. J., Jeon, B. S., Paek, S. H., Lee, K. M., Kim, J. Y., Lee, J. Y., et al. (2014). Long-term cognitive outcome of bilateral subthalamic deep brain stimulation in Parkinson’s disease. J. Neurosurg. 126, 1090–1096. doi: 10.3171/2014.4.jns13231

Li, H., Jia, J., and Yang, Z. (2016). Mini-Mental State Examination in Elderly Chinese: A Population-Based Normative Study. J. Alzheimers Dis. 53, 487–496. doi: 10.3233/JAD-160119

Litvan, I., Goldman, J. G., Troster, A. I., Schmand, B. A., Weintraub, D., Petersen, R. C., et al. (2012). Diagnostic criteria for mild cognitive impairment in Parkinson’s disease: Movement Disorder Society Task Force guidelines. Mov. Disord. 27, 349–356. doi: 10.1002/mds.24893

Lu, J., Li, D., Li, F., Zhou, A., Wang, F., Zuo, X., et al. (2011). Montreal cognitive assessment in detecting cognitive impairment in Chinese elderly individuals: A population-based study. J. Geriatr. Psychiatry Neurol. 24, 184–190. doi: 10.1097/JGPS.0b013e31821f7b7c

Nie, K., Gao, Y., Mei, M., Guo, M., Huang, Z., Wang, L., et al. (2019). The clinical characteristics and cognitive features of mild cognitive impairment in Parkinson’s disease and the analysis of relevant factors. J. Clin. Neurol. 63, 142–148. doi: 10.1001/jcn.2019.0121

Odekerken, V. J. J., Boel, J. A., Geurtsen, G. J., Schmand, B. A., Dekker, P. J., de Haan, R. J., et al. (2015). Neuropsychological outcome after deep brain stimulation for Parkinson’s disease. Neurology 84, 1355–1361. doi: 10.1212/WNL.0000000000001419

Okun, M. S., Fernandez-Daroca, J. H., Wu, S. S., Kirschg-Darrow, L., Bowers, D., Bova, P., et al. (2009). Cognition and mood in Parkinson’s disease in subthalamic nucleus versus globus pallidus interna deep brain stimulation: The COMPARE trial. Ann. Neurol. 65, 586–595. doi: 10.1002/ana.21596

Park, K. W., Jo, S., Kim, M. S., Choi, N., Jeon, S. R., Park, H. K., et al. (2020). Cognitive profile as a predictor of the long-term outcome after deep brain stimulation in Parkinson disease. J. Neurosurg. 127, 752–756. doi: 10.3171/2020.11.JNS2020063

Parsons, T. D., Rogers, S. A., Braaten, A. J., Woods, S. P., and Tröster, A. I. (2006). Cognitive sequelae of subthalamic nucleus deep brain stimulation in Parkinson disease: A meta-analysis. Lancet Neurol. 5, 578–588.

Rughani, A., Schwab, J. M., Sidtophoulos, C., Pilisus, J., Ramirez-Zamora, A., Sweet, J. A., et al. (2018). Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidance on Subthalamic Nucleus and Globus Pallidus Internus Deep Brain Stimulation for the Treatment of Patients With Parkinson’s Disease: Executive Summary. Neurosurgery 82, 753–756. doi: 10.1093/neuros/nyy307

Schröer, A., and Schott, J. M. (2006). Epidemiological, clinical, and genetic characteristics of early-onset parkinsonism. Lancet Neurol. 5, 355–363.

Smeding, H. M. M., Speelman, J. D., Huizenga, H. M., Schuurman, P. R., and Schmand, B. (2011). Predictors of cognitive and psychosocial outcome after STN DBS in Parkinson’s Disease. J. Neurosurg. Neurosurg. Psychiatry 82, 754–760. doi: 10.1136/jnnp.2007.140012

Stein, J., Lupp, M., Maier, W., Wagner, M., Wolfgruber, S., Scherer, M., et al. (2012). Assessing cognitive changes in the elderly: Reliable change indices for the Mini-Mental State Examination. Acta Psychr. Scand. 126, 208–218. doi: 10.1111/j.1600-0447.2012.01850.x
Temel, Y., Blokland, A., Steinbusch, H. W., and Visser-Vandewalle, V. (2005). The functional role of the subthalamic nucleus in cognitive and limbic circuits. *Prog. Neurobiol.* 76, 393–413. doi: 10.1016/j.pneurobio.2005.09.005

Yin, Z., Bai, Y., Zou, L., Zhang, X., Wang, H., Gao, D., et al. (2021). Balance response to levodopa predicts balance improvement after bilateral subthalamic nucleus deep brain stimulation in Parkinson’s disease. *NPJ Parkinsons Dis.* 7:47. doi: 10.1038/s41531-021-00192-9

York, M. K., Dulay, M., Macias, A., Levin, H. S., Grossman, R., Simpson, R., et al. (2008). Cognitive declines following bilateral subthalamic nucleus deep brain stimulation for the treatment of Parkinson’s disease. *J. Neurol. Neurosurg. Psychiatry* 79, 789–795. doi: 10.1136/jnnp.2007.118786

Zangaglia, R., Pacchetti, C., Pasotti, C., Mancini, F., Servello, D., Sinforiani, E., et al. (2009). Deep brain stimulation and cognitive functions in Parkinson’s disease: A three-year controlled study. *Mov. Disord.* 24, 1621–1628. doi: 10.1002/mds.22603

Zavala, B. A., Tan, H., Little, S., Ashkan, K., Hariz, M., Folhyne, T., et al. (2014). Midline frontal cortex low-frequency activity drives subthalamic nucleus oscillations during conflict. *J. Neurosci.* 34, 7322–7333. doi: 10.1523/JNEUROSCI.1169-14.2014